This is why they are going to retain the Novartis reps over you. We are experts at generating excitement for DED drugs that suck.I am already disenchanted and it just started. Providers smile at me and then go in the back room and laugh. “Omg another over zealous rep about a drop”
and will someone tell the field reimbursement team to back the F off. Talk about needing to justify their existence!!! Chill out!
This is why they are going to retain the Novartis reps over you. We are experts at generating excitement for DED drugs that suck.
I am already disenchanted and it just started. Providers smile at me and then go in the back room and laugh. “Omg another over zealous rep about a drop”
and will someone tell the field reimbursement team to back the F off. Talk about needing to justify their existence!!! Chill out!
Must be some East rep who can’t sell Miebo. Their numbers suck!!
Wait till you see your xiidra goals lol. Only way you win with xiidra is finishing last place, getting a big plan the following year, and flip flopping rankings. Guaranteed P club like the Northeast reps.True numbers are not out yet. STFU.
it’s over zealous quotas.
We don't want to hear about your excuses, only your solutions. If you can't outsell a drug that takes 3 months to work, then maybe this isn't the right industry for you. It's a level playing field out there--the only difference is the talent in the territory!it’s over zealous quotas.
Please come back in a few months and see how your story changes. There is a reason branded Restasis maintains a 70 market share and still is doing well with multiple generics on the market.We don't want to hear about your excuses, only your solutions. If you can't outsell a drug that takes 3 months to work, then maybe this isn't the right industry for you. It's a level playing field out there--the only difference is the talent in the territory!
Please come back in a few months and see how your story changes. There is a reason branded Restasis maintains a 70 market share and still is doing well with multiple generics on the market.
Why would doctors be excited? The Miebo drug is available over the counter in Europe for $20 and B&L bought it so they can Epipen the shit out of it and charge 40-50x that LITERALLY.
Doctors know it will take 2-3 years on the market at least for the out of pocket price to go down. That’s why B&L bought Xiidra because they know you guys are going to have trouble breaking into the market with Miebo, so buying a competitor makes it a softer landing for their stock price if Miebo flops (which it fucking should because of how greedy we’re being pricing it).
If you look right now on GoodRx, patients’ insurance (if they have it) is being charged $700-$1000 for a monthly supply instead of $15-$20 over the counter in Europe for the same exact drug.
Meanwhile, Vision Care and Surgical are bleeding out our asses because of lack of supply availability. We don’t have the resources to fix those issues because the company decided writing a check to our competitor for $2.1 billion to buy Xiidra and Blink was the only way to save their Miebo launch.
I’m disgusted with the direction of this company. We became a stand alone company only so we can price gouge people on Miebo and clear enough debt to buy up the competitive products doctors would pivot to instead. Bad business all with the focus on stock price alone. No vision for the company except selling off Vision Care to Essilor or something to make their numbers in 5 years.
Vision care will never be soldWhy would doctors be excited? The Miebo drug is available over the counter in Europe for $20 and B&L bought it so they can Epipen the shit out of it and charge 40-50x that LITERALLY.
Doctors know it will take 2-3 years on the market at least for the out of pocket price to go down. That’s why B&L bought Xiidra because they know you guys are going to have trouble breaking into the market with Miebo, so buying a competitor makes it a softer landing for their stock price if Miebo flops (which it fucking should because of how greedy we’re being pricing it).
If you look right now on GoodRx, patients’ insurance (if they have it) is being charged $700-$1000 for a monthly supply instead of $15-$20 over the counter in Europe for the same exact drug.
Meanwhile, Vision Care and Surgical are bleeding out our asses because of lack of supply availability. We don’t have the resources to fix those issues because the company decided writing a check to our competitor for $2.1 billion to buy Xiidra and Blink was the only way to save their Miebo launch.
I’m disgusted with the direction of this company. We became a stand alone company only so we can price gouge people on Miebo and clear enough debt to buy up the competitive products doctors would pivot to instead. Bad business all with the focus on stock price alone. No vision for the company except selling off Vision Care to Essilor or something to make their numbers in 5 years.
Vision care will never be sold
Why would doctors be excited? The Miebo drug is available over the counter in Europe for $20 and B&L bought it so they can Epipen the shit out of it and charge 40-50x that LITERALLY.
Doctors know it will take 2-3 years on the market at least for the out of pocket price to go down. That’s why B&L bought Xiidra because they know you guys are going to have trouble breaking into the market with Miebo, so buying a competitor makes it a softer landing for their stock price if Miebo flops (which it fucking should because of how greedy we’re being pricing it).
If you look right now on GoodRx, patients’ insurance (if they have it) is being charged $700-$1000 for a monthly supply instead of $15-$20 over the counter in Europe for the same exact drug.
Meanwhile, Vision Care and Surgical are bleeding out our asses because of lack of supply availability. We don’t have the resources to fix those issues because the company decided writing a check to our competitor for $2.1 billion to buy Xiidra and Blink was the only way to save their Miebo launch.
I’m disgusted with the direction of this company. We became a stand alone company only so we can price gouge people on Miebo and clear enough debt to buy up the competitive products doctors would pivot to instead. Bad business all with the focus on stock price alone. No vision for the company except selling off Vision Care to Essilor or something to make their numbers in 5 years.
What actions? Talk is cheapBrent Saunders’ actions say otherwise
Current situation is a consequence of Papa’s and his leadership team (Ackermann and others) management.
Current situation is a consequence of Papa’s and his leadership team (Ackermann and others) management.
